Is SEER or HBIO more profitable?

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Seer -478.05% -27.23% -23.99% Harvard Bioscience -11.86% -33.13% -4.80%

Do analysts recommend CSBR or HBIO?

Harvard Bioscience has a consensus target price of $6.75, indicating a potential downside of 20.59%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Champions Oncology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Champions Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Harvard Bioscience 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, HBIO or IBAC?

IB Acquisition has lower revenue, but higher earnings than Harvard Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harvard Bioscience $86.55M 0.45 -$56.70M -$2.31 N/A IB Acquisition N/A N/A N/A N/A N/A

Harvard Bioscience (HBIO) Competitors

$8.67 +0.17 (+2.00%)

As of 12:09 PM Eastern

Compare

HBIO vs. MXCT, SEER, CSBR, HYFT, and IBAC

Should you buy Harvard Bioscience stock or one of its competitors? Harvard Bioscience's main competitors and comparable companies include MaxCyte (MXCT), Seer (SEER), Champions Oncology (CSBR), MindWalk (HYFT), and IB Acquisition (IBAC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Harvard Bioscience compare to MaxCyte?

MaxCyte (NASDAQ:MXCT) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

68.8% of MaxCyte shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 4.1% of MaxCyte shares are held by insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MaxCyte presently has a consensus price target of $5.00, indicating a potential upside of 362.96%. Harvard Bioscience has a consensus price target of $6.75, indicating a potential downside of 20.59%. Given MaxCyte's higher probable upside, analysts plainly believe MaxCyte is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MaxCyte	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MaxCyte has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

MaxCyte has higher earnings, but lower revenue than Harvard Bioscience. Harvard Bioscience is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MaxCyte	$33.03M	3.37	-$44.63M	-$0.33	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

In the previous week, MaxCyte's average media sentiment score of 0.00 equaled Harvard Bioscience'saverage media sentiment score.

Company	Overall Sentiment
MaxCyte	Neutral
Harvard Bioscience	Neutral

Harvard Bioscience has a net margin of -11.86% compared to MaxCyte's net margin of -114.77%. MaxCyte's return on equity of -18.92% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MaxCyte	-114.77%	-18.92%	-16.14%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Summary

MaxCyte and Harvard Bioscience tied by winning 6 of the 12 factors compared between the two stocks.

How does Harvard Bioscience compare to Seer?

Seer (NASDAQ:SEER) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

75.2% of Seer shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 11.3% of Seer shares are held by insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Seer had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 1 mentions for Seer and 0 mentions for Harvard Bioscience. Seer's average media sentiment score of 0.87 beat Harvard Bioscience's score of 0.00 indicating that Seer is being referred to more favorably in the media.

Company	Overall Sentiment
Seer	Positive
Harvard Bioscience	Neutral

Seer currently has a consensus target price of $4.00, indicating a potential upside of 71.67%. Harvard Bioscience has a consensus target price of $6.75, indicating a potential downside of 20.59%. Given Seer's stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seer	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Harvard Bioscience has a net margin of -11.86% compared to Seer's net margin of -478.05%. Seer's return on equity of -27.23% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seer	-478.05%	-27.23%	-23.99%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Seer has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Harvard Bioscience has higher revenue and earnings than Seer. Harvard Bioscience is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seer	$16.58M	7.78	-$73.60M	-$1.22	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

Summary

Seer beats Harvard Bioscience on 9 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to Champions Oncology?

Champions Oncology (NASDAQ:CSBR) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

In the previous week, Champions Oncology had 2 more articles in the media than Harvard Bioscience. MarketBeat recorded 2 mentions for Champions Oncology and 0 mentions for Harvard Bioscience. Champions Oncology's average media sentiment score of 0.89 beat Harvard Bioscience's score of 0.00 indicating that Champions Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Champions Oncology	Positive
Harvard Bioscience	Neutral

Champions Oncology has a beta of 0.44, meaning that its stock price is 56% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Champions Oncology has higher earnings, but lower revenue than Harvard Bioscience. Champions Oncology is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Champions Oncology	$59.42M	1.16	-$1.17M	-$0.08	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

Champions Oncology has a net margin of -1.82% compared to Harvard Bioscience's net margin of -11.86%. Champions Oncology's return on equity of -25.77% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Champions Oncology	-1.82%	-25.77%	-3.71%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

Harvard Bioscience has a consensus target price of $6.75, indicating a potential downside of 20.59%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Harvard Bioscience is more favorable than Champions Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Champions Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

41.3% of Champions Oncology shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 46.3% of Champions Oncology shares are held by company insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Champions Oncology beats Harvard Bioscience on 9 of the 16 factors compared between the two stocks.

How does Harvard Bioscience compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, media sentiment, dividends, risk, analyst recommendations, earnings and valuation.

Harvard Bioscience has a net margin of -11.86% compared to MindWalk's net margin of -105.11%. Harvard Bioscience's return on equity of -33.13% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-105.11%	-133.26%	-77.78%
Harvard Bioscience	-11.86%	-33.13%	-4.80%

MindWalk currently has a consensus price target of $5.00, indicating a potential upside of 235.57%. Harvard Bioscience has a consensus price target of $6.75, indicating a potential downside of 20.59%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than Harvard Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

MindWalk has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Harvard Bioscience has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

In the previous week, MindWalk had 3 more articles in the media than Harvard Bioscience. MarketBeat recorded 3 mentions for MindWalk and 0 mentions for Harvard Bioscience. MindWalk's average media sentiment score of 0.24 beat Harvard Bioscience's score of 0.00 indicating that MindWalk is being referred to more favorably in the media.

Company	Overall Sentiment
MindWalk	Neutral
Harvard Bioscience	Neutral

MindWalk has higher earnings, but lower revenue than Harvard Bioscience. MindWalk is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$11.24M	6.19	-$10.11M	-$0.26	N/A
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A

6.7% of MindWalk shares are held by institutional investors. Comparatively, 80.9% of Harvard Bioscience shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 17.0% of Harvard Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

MindWalk beats Harvard Bioscience on 9 of the 17 factors compared between the two stocks.

How does Harvard Bioscience compare to IB Acquisition?

Harvard Bioscience (NASDAQ:HBIO) and IB Acquisition (NASDAQ:IBAC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

In the previous week, IB Acquisition had 1 more articles in the media than Harvard Bioscience. MarketBeat recorded 1 mentions for IB Acquisition and 0 mentions for Harvard Bioscience. Harvard Bioscience's average media sentiment score of 0.00 equaled IB Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Harvard Bioscience	Neutral
IB Acquisition	Neutral

Harvard Bioscience presently has a consensus target price of $6.75, suggesting a potential downside of 20.59%. Given Harvard Bioscience's stronger consensus rating and higher possible upside, equities research analysts plainly believe Harvard Bioscience is more favorable than IB Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harvard Bioscience	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
IB Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IB Acquisition has lower revenue, but higher earnings than Harvard Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harvard Bioscience	$86.55M	0.45	-$56.70M	-$2.31	N/A
IB Acquisition	N/A	N/A	N/A	N/A	N/A

80.9% of Harvard Bioscience shares are owned by institutional investors. 17.0% of Harvard Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

IB Acquisition has a net margin of 0.00% compared to Harvard Bioscience's net margin of -11.86%. IB Acquisition's return on equity of 0.00% beat Harvard Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harvard Bioscience	-11.86%	-33.13%	-4.80%
IB Acquisition	N/A	N/A	N/A

Summary

Harvard Bioscience beats IB Acquisition on 6 of the 10 factors compared between the two stocks.

Get Harvard Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HBIO vs. The Competition

Export

Metric	Harvard Bioscience	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.55M	$10.70B	$7.12B	$13.48B
Dividend Yield	N/A	1.45%	2.54%	17.38%
P/E Ratio	-3.76	32.07	274.29	26.31
Price / Sales	0.46	107.86	597.80	86.06
Price / Cash	0.71	27.32	27.22	34.70
Price / Book	2.82	6.78	11.10	6.39
Net Income	-$56.70M	$57.48B	$3.50B	$381.19M
7 Day Performance	8.94%	0.38%	-1.84%	-0.18%
1 Month Performance	8.13%	7.71%	-6.54%	-4.41%
1 Year Performance	97.09%	31.25%	6.12%	1.68%

Harvard Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HBIO Harvard Bioscience	0.8299 of 5 stars	$8.67 +2.0%	$6.75 -22.1%	+89.3%	$39.45M	$86.55M	N/A	339
MXCT MaxCyte	3.4066 of 5 stars	$1.18 +1.7%	$5.00 +323.7%	-36.8%	$121.79M	$33.03M	N/A	91
SEER Seer	3.6616 of 5 stars	$2.15 +5.9%	$4.00 +86.0%	+2.2%	$119.05M	$16.58M	N/A	124
CSBR Champions Oncology	0.7408 of 5 stars	$5.01 +1.7%	N/A	-21.9%	$69.80M	$59.42M	N/A	214
HYFT MindWalk	2.8067 of 5 stars	$1.38 +3.0%	$5.00 +262.3%	N/A	$64.46M	$11.24M	N/A	77	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HBIO) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harvard Bioscience (HBIO) Competitors

HBIO vs. MXCT, SEER, CSBR, HYFT, and IBAC

How does Harvard Bioscience compare to MaxCyte?

Summary

How does Harvard Bioscience compare to Seer?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Summary

How does Harvard Bioscience compare to MindWalk?

Summary

How does Harvard Bioscience compare to IB Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harvard Bioscience (HBIO) Competitors

HBIO vs. MXCT, SEER, CSBR, HYFT, and IBAC

How does Harvard Bioscience compare to MaxCyte?

Do insiders and institutionals believe in MXCT or HBIO?

Do analysts rate MXCT or HBIO?

Which has more volatility & risk, MXCT or HBIO?

Which has better earnings & valuation, MXCT or HBIO?

Does the media prefer MXCT or HBIO?

Is MXCT or HBIO more profitable?

Summary

How does Harvard Bioscience compare to Seer?

Do insiders & institutionals have more ownership in SEER or HBIO?

Does the media prefer SEER or HBIO?

Do analysts rate SEER or HBIO?

Is SEER or HBIO more profitable?

Which has more volatility and risk, SEER or HBIO?

Which has higher valuation & earnings, SEER or HBIO?

Summary

How does Harvard Bioscience compare to Champions Oncology?

Does the media favor CSBR or HBIO?

Which has more volatility and risk, CSBR or HBIO?

Which has higher earnings & valuation, CSBR or HBIO?

Is CSBR or HBIO more profitable?

Do analysts recommend CSBR or HBIO?

Do insiders & institutionals have more ownership in CSBR or HBIO?

Summary

How does Harvard Bioscience compare to MindWalk?

Is HYFT or HBIO more profitable?

Do analysts rate HYFT or HBIO?

Which has more volatility & risk, HYFT or HBIO?

Does the media favor HYFT or HBIO?

Which has stronger earnings and valuation, HYFT or HBIO?

Do institutionals and insiders believe in HYFT or HBIO?

Summary

How does Harvard Bioscience compare to IB Acquisition?

Does the media prefer HBIO or IBAC?

Do analysts rate HBIO or IBAC?

Which has preferable earnings and valuation, HBIO or IBAC?

Do institutionals and insiders hold more shares of HBIO or IBAC?

Is HBIO or IBAC more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HBIO vs. The Competition

Harvard Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools